DE60327007D1 - Procedure for cardiovascular diseases - Google Patents

Procedure for cardiovascular diseases

Info

Publication number
DE60327007D1
DE60327007D1 DE60327007T DE60327007T DE60327007D1 DE 60327007 D1 DE60327007 D1 DE 60327007D1 DE 60327007 T DE60327007 T DE 60327007T DE 60327007 T DE60327007 T DE 60327007T DE 60327007 D1 DE60327007 D1 DE 60327007D1
Authority
DE
Germany
Prior art keywords
calprotectin
antibody
procedure
cardiovascular diseases
body fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327007T
Other languages
German (de)
Inventor
Erling Sundrehagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axis Shield ASA
Original Assignee
Axis Shield ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield ASA filed Critical Axis Shield ASA
Application granted granted Critical
Publication of DE60327007D1 publication Critical patent/DE60327007D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Abstract

The present invention provides an assay method for the determination of calprotectin in a calprotectin-containing body fluid, said method comprising the steps of: (a) obtaining a calprotectin-containing liquid sample of, or derived from, said fluid; (b) contacting said sample of said body fluid with a nanoparticle-bound anti-calprotectin antibody or antibody fragment, to bind said calprotectin; and (c)assessing the calprotectin content by turbidimetry, wherein the diameter of the antibody or antibody fragment coated nanoparticles is in the range 65-140 nm.
DE60327007T 2002-12-20 2003-12-22 Procedure for cardiovascular diseases Expired - Lifetime DE60327007D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229747.1A GB0229747D0 (en) 2002-12-20 2002-12-20 Assay

Publications (1)

Publication Number Publication Date
DE60327007D1 true DE60327007D1 (en) 2009-05-14

Family

ID=9950111

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60317931T Expired - Lifetime DE60317931T2 (en) 2002-12-20 2003-12-22 CVD ASSAY
DE60327007T Expired - Lifetime DE60327007D1 (en) 2002-12-20 2003-12-22 Procedure for cardiovascular diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60317931T Expired - Lifetime DE60317931T2 (en) 2002-12-20 2003-12-22 CVD ASSAY

Country Status (16)

Country Link
US (3) US10101325B2 (en)
EP (2) EP1573335B1 (en)
JP (2) JP4653492B2 (en)
CN (3) CN101893635B (en)
AT (2) ATE380345T1 (en)
AU (1) AU2003295142A1 (en)
CA (2) CA2504876A1 (en)
DE (2) DE60317931T2 (en)
DK (2) DK1739430T3 (en)
ES (2) ES2323475T3 (en)
GB (1) GB0229747D0 (en)
NO (1) NO20052161L (en)
PL (2) PL394295A1 (en)
PT (1) PT1573335E (en)
SI (1) SI1573335T1 (en)
WO (1) WO2004057341A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
JP4447641B2 (en) 2004-07-23 2010-04-07 アスペンビオ， ファーマ， インコーポレイテッド Methods and devices for diagnosing appendicitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
EP1862805A1 (en) * 2006-06-01 2007-12-05 University of Zürich The use of mrp 8/14 levels for discrimination of individuals at risk of acute coronary syndromes
WO2010101950A1 (en) * 2009-03-02 2010-09-10 Catholic Healthcare West Diagnostic devices and methods of use
WO2010128033A2 (en) * 2009-05-07 2010-11-11 Novozymes A/S Method for purification of target polypeptides
US9574977B2 (en) * 2013-02-26 2017-02-21 Innova Prep Liquid to liquid biological particle concentrator with disposable fluid path
EP2511704A1 (en) 2011-04-13 2012-10-17 Immundiagnostik AG Assay method for intrinsic acute kidney injury
NO20110895A1 (en) * 2011-06-21 2012-12-24 Magne Fagerhol Competitive S100A9 immunoassays
ES2402457B2 (en) * 2011-10-19 2014-01-20 Universidade De Vigo PROCEDURE FOR THE DIAGNOSIS OF SPILL PLEURAL MALIGNO THROUGH THE DETERMINATION OF THE CONCENTRATION OF CALPROTECTINE IN PLEURAL LIQUID.
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
US9594999B2 (en) 2012-04-03 2017-03-14 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
NZ706155A (en) * 2012-09-12 2018-09-28 Berg Llc Use of markers in the identification of cardiotoxic agents
WO2014149926A1 (en) 2013-03-15 2014-09-25 X-Card Holdings, Llc Methods of making a core layer for an information carrying card, and resulting products
WO2018146129A1 (en) * 2017-02-07 2018-08-16 Orthogenics As Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
EP3385712A1 (en) 2017-04-03 2018-10-10 Gentian AS Improved calprotectin assay
BR112019023210A2 (en) * 2017-05-09 2020-05-26 Immundiagnostik Ag METHOD FOR DETERMINING MEMBERS OF THE S100 FAMILY OF CALCIUM-BINDING PROTEINS THROUGH IMMUNOTURBIDIMETRY
CN108196066A (en) * 2018-01-22 2018-06-22 安徽伊普诺康生物技术股份有限公司 A kind of kit for measuring calcium sozin and its preparation application method
CN111819577A (en) 2018-03-07 2020-10-23 X卡控股有限公司 Metal card
CN115836223A (en) * 2020-05-13 2023-03-21 北欧生物科技公司 Calprotectin assay

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287202A (en) 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
JPS55162059A (en) * 1979-06-05 1980-12-17 Mochida Pharmaceut Co Ltd Measuring method for antigen, antibody or their complex and measurement reagent kit
US4401765A (en) * 1981-09-01 1983-08-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
US4480042A (en) * 1981-10-28 1984-10-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS60139621A (en) 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd Antithrombotic agent
JPS625970A (en) 1985-03-15 1987-01-12 Terumo Corp Pyrazine derivative and platelet coagulation inhibitor containing same
EP0310361A3 (en) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
GB2218100A (en) 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
ATE139845T1 (en) * 1989-08-23 1996-07-15 Canon Kk METHOD FOR MEASURING AN IMMUNOLOGICALLY ACTIVE MATERIAL AND DEVICE SUITABLE FOR THE SAME
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
PT937259E (en) * 1996-11-01 2005-01-31 Magne K Fagerhol PROCESS FOR EXTRACTION OF PROTEINS
AU7100898A (en) 1997-04-02 1998-10-22 Brigham And Women's Hospital Means of ascertaining an individual's risk profile for atherosclerotic disease
GB9816088D0 (en) 1998-07-23 1998-09-23 Axis Biochemicals Asa System
EP1105739A1 (en) * 1998-08-20 2001-06-13 Axis-Shield Asa Assay method for cardiovascular disease
US7622259B1 (en) * 1999-07-05 2009-11-24 K.U. Leuven Research & Development Detection of von-Willebrand factor (vWF) activity
JP2003508453A (en) 1999-08-31 2003-03-04 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerosis
FR2800636A1 (en) * 1999-11-05 2001-05-11 Bio Merieux COMPOSITE PARTICLES, DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND USES
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
DE60139408D1 (en) * 2000-08-29 2009-09-10 Kyowa Medex Co Ltd GOOD REPRODUCIBLE AGGLUTINATION IMMUNOASSAY PROCEDURE AND REAGENTS
JP2002318233A (en) * 2001-04-19 2002-10-31 Shino Test Corp Nephelometric measuring reagent and method for measuring substance to be measured
EP2261669A1 (en) * 2001-05-04 2010-12-15 Alere San Diego, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
FR2872579B1 (en) * 2004-06-30 2006-11-24 Pasteur Institut DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation

Also Published As

Publication number Publication date
ATE380345T1 (en) 2007-12-15
CN101893635A (en) 2010-11-24
JP2010019849A (en) 2010-01-28
PL394295A1 (en) 2011-09-12
US20060134705A1 (en) 2006-06-22
NO20052161D0 (en) 2005-05-03
JP4653492B2 (en) 2011-03-16
JP2006510895A (en) 2006-03-30
EP1573335B1 (en) 2007-12-05
US20110318847A1 (en) 2011-12-29
WO2004057341A3 (en) 2004-10-21
PL216385B1 (en) 2014-03-31
CN102608326A (en) 2012-07-25
WO2004057341A2 (en) 2004-07-08
CN101893635B (en) 2014-04-09
DE60317931T2 (en) 2008-11-13
CA2729365A1 (en) 2004-07-08
JP5744385B2 (en) 2015-07-08
NO20052161L (en) 2005-07-19
SI1573335T1 (en) 2008-04-30
EP1573335A2 (en) 2005-09-14
US20190049439A1 (en) 2019-02-14
DK1573335T3 (en) 2008-04-14
EP1739430B1 (en) 2009-04-01
ATE427498T1 (en) 2009-04-15
PT1573335E (en) 2007-12-21
ES2297250T3 (en) 2008-05-01
CN1729398B (en) 2012-04-04
DK1739430T3 (en) 2009-07-13
CA2729365C (en) 2018-09-18
AU2003295142A1 (en) 2004-07-14
DE60317931D1 (en) 2008-01-17
US10101325B2 (en) 2018-10-16
EP1739430A3 (en) 2007-01-17
EP1739430A2 (en) 2007-01-03
CN1729398A (en) 2006-02-01
ES2323475T3 (en) 2009-07-16
PL377476A1 (en) 2006-02-06
CA2504876A1 (en) 2004-07-08
GB0229747D0 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
NO20052161D0 (en) Method of analysis for cardiovascular disease
Sener et al. Rapid real-time detection of procalcitonin using a microcontact imprinted surface plasmon resonance biosensor
Ertürk et al. Microcontact imprinting based surface plasmon resonance (SPR) biosensor for real-time and ultrasensitive detection of prostate specific antigen (PSA) from clinical samples
JP2019535015A5 (en)
NO20076656L (en) Improved immunoassay methods
WO2007011936A3 (en) Lateral flow assay and device using magnetic particles
WO2010038974A3 (en) Composition and kit for diagnosing immunoglobulin a nephropathy and tgbm nephropathy
ATE538386T1 (en) DETECTION OF CANCER USING INCREASED BCL-2 CONCENTRATIONS
RU2011125320A (en) METHODS, DEVICES, AND KITS FOR DETECTION OR MONITORING OF ACUTE KIDNEY DAMAGE
JP2012509477A5 (en)
EP2538218A8 (en) Biochemical markers for CVD risk assessment
ATE411525T1 (en) DETECTION OF HISTONE MODIFICATION IN CELL-FREE NUCLEOSOMES
AU2004256206A1 (en) Device and method for simultaneous carrying out of blood group determination, serum cross-check and antibody detection test
WO2007061793A3 (en) Modified cardiolipin and uses therefor
DE602006021777D1 (en) DIAGNOSTIC PROCEDURE FOR PRE-CLAMPING
Kim et al. Gold nanoparticle-based signal augmentation of quartz crystal microbalance immunosensor measuring C-reactive protein
Kurihara et al. Fabrication of carboxylated silicon nitride sensor chips for detection of antigen–antibody reaction using microfluidic reflectometric interference spectroscopy
Pasinszki et al. Advances in celiac disease testing
DE60130919D1 (en) FLOW DEVICE, DIAGNOSTIC KIT CONTAINING THESE AND USE FOR THE DETECTION OF ANALYTES IN A SAMPLE
WO2008067008A3 (en) A method for the quantitative evaluation of sex hormones in a serum sample
DE602005010548D1 (en) IMPROVED METHOD FOR DIAGNOSIS OF ACUTE CORONARY SYNDROME
WO2008067007A3 (en) A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
DE602004019134D1 (en) FAST DETERMINATION OF VARIOUS FORMS OF HGF (HEPTOCYTE GROWTH FACTOR) IN BODY FLUIDS
ATE520985T1 (en) METHOD FOR DETERMINING ANTIGEN AND ANTIBODIES AGAINST THE ANTIGEN
WO2008066997A3 (en) A method for quantitative measurement of cardiac biochemical markers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KUDLEK & GRUNERT PATENTANWAELTE PARTNERSCHAFT, 803

R082 Change of representative

Ref document number: 1739430

Country of ref document: EP

Representative=s name: KUDLEK & GRUNERT PATENTANWAELTE PARTNERSCHAFT, 803